



TONOLO, Giancarlo

April 26th 2020

Personal Details

Date of Birth: 17-Mar-1957

Gender: **Male**

Country and Place of Birth: **Italy**

First nationality: **Italy**

Permanent Address:

**via delle vigne snc
Loiri Porto San Paolo
I-07020
Italy**

Home telephone: *Professional* *Mobile*
+390789552418/416 *telephone:* *telephone:*
+390789552411 +393316487334

Other details

E-mail for correspondence:
giancarlo.tonolo@atssardegna.it

Other e-mail address:
giancarlo-tonolo@gmail.com

Areas of Expertise

Hypertension, Diabetes, Obesity : Clinical and research

Language Skills

Mother Tongue 1 : **Italian**

U.N. Proficiency Examination No

<i>Working Languages</i>	<i>Speaking</i>	<i>Reading</i>	<i>Writing</i>
English	Advanced	Advanced	Advanced
French	None	None	None
Spanish	None	None	None

Other languages

Education

Highest Educational Degree

University Degree

Please indicate other educational details or studies in progress in the text box below (if applicable, publications may be entered in the Additional Information section)

university degree in MEDICINE MD University degree (diploma) in Cardiology PhD in Metabolic disease

Educational details

<i>Year</i>	<i>Name of Education Institution</i>	<i>Degree / Title of degree/diploma and Diploma description of studies</i>
1999	Faculty of Medicine and Surgery	Ph. D. PhD in metabolic disease three years
2002	Sassari , province of Sassari Italy	University course with presentation of final discussion and peer reviewed papers
1982	Faculty of Medicine and Surgery	Diploma Specialization in Cardiology four year
1986	Sassari, Province of Sassari, Italy Italy	University course
1976	Faculty of Medicine and Surgery	M.D. Medical Doctor six years
1982	Sassari, Province of Sassary, Italy Italy	University course

International Experience

<i>Organization:</i>	<i>Duty Station:</i>	<i>From: - To:</i>	<i>Grade:</i>
university Lund,Sweden	Medical Genetics Unit,Wallenberg Laboratory	2002 - 2003	Visiting professor
WesternInfirmarYGlasgowUK	MRCBloodPressureUnit	1984 - 1987	registrar

African Region Zimbabwe, research in type 2 diabetes from Sassari University to Harare University for joint projects in type 2 diabetes

Present and previous employment

Exact Title of **Director and Head of department diabetology ASSL Olbia, Italy**

Position held:

Name/address **ASSL Olbia. Via Bazzoni-Sircana 2,** Name and **P Tauro General Director**
of employer: **07026 Olbia, Italy** title of **ASSL Olbia**
supervisor(s):

From:-To: **february 2006 - Present**

Brief description of duties and responsibilities:

Director and Head of department diabetology ASSL Olbia with centers in three hospitals. Chief Diabetologist with direct supervision of 7 Medical Doctors,18 nurses,2 biologic nutritionists, 1 dietician,1 psicologist

Key achievements:

care of more than 11,000 diabetic patients, clinical research collaborations in diabetic nephropathy and gender medicine, teaching to GPs,implementation of local strategies (nutrition, excercise) to prevent obesity, diabetes and hypertension, high type 1 diabetes technology (CSII, CSII-SAP,CSII-LGL, CIIP)

Exact Title of **assistant professor diabetology**

Position held:

Name/address **university hospital. University of** Name and **prof Mario Maioli**
of employer: **Sassari, Italy** title of
supervisor(s):

From:-To: **6/1990 - 1/2006**

Brief description of duties and responsibilities:

Diabetes outpatient clinic, supervisor young MD, clinical and experimental research(mainly diabetic nephropathy and hypertension). Contract Professor in nutrition, tutor for MD and Biologist in the specialization school of "Diet and nutrition" University of Sassari

Key achievements:

**Publications in peer reviewed journals listed in PUBMED
see attached**

Please indicate how many people you **25** May we contact your employer as **Yes**
were responsible for. a reference?

Reason for leaving: **NEW JOB AS DIRECTOR ASSL OLBIA FROM FEBRUARY
2006**

Exact Title of **Visiting Professor**

Position held:

Name/address **Univeristy Hopsital MAS, Malmö,** Name and **Professor Holger luthman**
of employer: **Lund University, Sweden** title of
supervisor(s):

From:-To: **9/2002 - 2/2003**

Brief description of duties and responsibilities:

1-genetic expression in diabetic nephropathy

2-co-supervision of two PhD student

Key achievements:

Publication of the following papers:

Comparative sequence analysis of the non-protein-coding mitochondrial DNA of inbred rat strains. PLoS One. 2009,4(12):e8148.

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

Kidney Int. 2006,70(1):177-86.

Epitope-restricted 65-kilodalton glutamic acid decarboxylase autoantibodies among new-onset Sardinian type 2 diabetes patients define phenotypes of autoimmune diabetes..

J Clin Endocrinol Metab. 2004;89(11):5675-82.

Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms.

Diabetes. 2005;54(1):228-33.

Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes.

J Nephrol. 2003,16, Suppl 7:S42-7. Review

Relationship between blood glucose control, pathogenesis and progression of diabetic nephropathy.

J Am Soc Nephrol. 2004;15 Suppl 1:S1-5. Review.

Please indicate how many people you were responsible for. **2** *May we contact your employer as a reference?* **Yes**

Reason for leaving: **end of project, full job at the Sassari University, Sassari, Italy**

Exact Title of **medical Doctor**

Position held:

Name/address of employer: **ASL 1 Sassari
General Hospital Sassari,**

Name and title of supervisor(s):

From:-To: **5/1987 - 5/1990**

Brief description of duties and responsibilities:

accident and emergency department in a general hospital , full time employment

Key achievements:

increased skill in emergency care

Please indicate how many people you were responsible for. **4** *May we contact your employer as a reference?* **Yes**

Reason for leaving: **full time employment in University Hospital in Sassari as diabetologist**

Exact Title of **Research Registrar**

Position held:

Name/address of employer: **MRC Blood Pressure Unit, Western
Infirmary, Glasgow, UK**

Name and title of

Dr AF Lever Director

supervisor(s):

From:-To: 11/1984 - 3/1987

Brief description of duties and responsibilities:

laboratory research on the development of a radioimmunoassay for Atrial Natriuretic Factor and clinical and animal studies to understand the physiology of Atrial Natriuretic Factor

Key achievements:

18 peer reviewed papers in international journals as author and coauthor , expertise in clinical and experimental research

Please indicate how many people you were responsible for. **3** May we contact your employer as a reference? **Yes**

Reason for leaving: **back to Italy to apply in Italy the research experience acquired in UK**

Computer Skills

Wordprocessor:	microsoft word processor	Working Knowledge
Database:	Access	Proficient
Spreadsheet:	Excell	Proficient
Operating Systems:	Windows	Working Knowledge
Internet & e-mail:	Internet explorer,Mozilla Firefox etc	Working Knowledge
Presentation:	power point	Proficient
Programming:		----

Family Info

Dependant family members

Name:	Date of birth:	Relationship:
Gianluca Tonolo	2-july 1986	son
Gianmarco Tonolo	21-Feb-1989	son
Claudia Tonolo	30-Jul-1995	daughter
Matteo Tonolo	16-Oct-2009	son
Paolo Tonolo	11-Nov-2014	son

References

<i>Name:</i>	<i>Address: Telephone: Fax:</i>	<i>E-mail: Occupation, business title:</i>	<i>Briefly indicate how you know this person:</i>
Holger Luthman MD PhD	medical genetics unit, Wallenberg laboratory, UMAS, Ingng 46. Plan 3. SE 205 02. Malmo, Sweden +46 040391152 +46 040331161	holger.luthman@med.lu.se professor genetics University Lund Sweden	collaboration in genetics type 2 diabetes
Ake Lernmark	university of Washington, Seatte, USA Dep endocrinology, clinical science, university hospital MAS, Malmo.Sweden +4640164247	ake.lernmark@med.lu.se professor of medicine and experimental diabetes	collaboration in autoimmunity of diabetes

Length of stay at current *in current country of residence since:* **17-Mar-1957** in current town/city place of residence *since:* **6-Feb-2006**

Additional Information

Relevant experience, living abroad, additional skills

September 2014-september 2017 President of the Sardinian branch of SIMDO (Italia Society of Metabolism, Obesity and Diabetes) and member of the National Directory Board of SIMDO

May 2009-May 2013 President of the Sardinina Branch of AMD (Italian Association of Medical Diabetologist)

March 2008 –March 2009 Scientific Responsibility for the Sardinina Project "Depression as a possible risk factor for type 2 diabetes onset "

May 2004-May 2008 member of the Italian Directory Board SID (Italian Society of Diabetology) may 2004-May 2008.

January 2000-January 2004 Member of Coordination Board of the Type 1 diabetes Study Group of the Italian Society of Diabetology (SID) (Director prof Aldo Galluzzo, Palermo University)

Randomized Clinical Trials experience:

Co-investigator in more than 20 RCT from 1986-to 2005

Principal investigator in 12 RCT from 2006 till now:

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.

Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O; **SMILE Study Group**. *Lancet Diabetes Endocrinol*. 2019 Jun;7(6):462-472. doi: 10.1016/S2213-8587(19)30150-0. Epub 2019 Apr 29.

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. Mirijello A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Russo GT, Guida P, Pontremoli R, De Cosmo S; **AMD ANNALS Study Group**. *BMC Nephrol*. 2018 Dec 4;19(1):347. doi: 10.1186/s12882-018-1136-6.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; **Harmony Outcomes committees and investigators**. *Lancet*. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

Efficacy of self-monitoring blood glucose as a key component of a chronic care model versus usual care in type 2 diabetes patients treated with oral agents: results of a randomized trial.

Musacchio N, Ciullo I, Scardapane M, Giancaterini A, Pessina L, Maino S, Gaiofatto R, Nicolucci A, Rossi MC; **Self-Care Study Group**.

Acta Diabetol. 2018 Mar;55(3):295-299. doi: 10.1007/s00592-017-1072-0. Epub 2017 Nov 14. No abstract available.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; **DEVOTE Study Group**. *N Engl J Med*. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; **SUSTAIN-6 Investigators**. *N Engl J Med*. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; **DEVOTE Study Group**. *N Engl J Med*. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; **SUSTAIN-6 Investigators**. *N Engl J Med*. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; **NN9068-3697 (DUAL-I) trial investigators**. *Lancet Diabetes Endocrinol*. 2014 Nov;2(11):885-93..

Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Viazzi F, Pontremoli R; **AMD-Annals Study Group**. *Nephrol Dial Transplant*. 2014 Mar;29(3):657-62.

Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; **PRISMA Study Group**. *Diabetes Care*. 2013 Oct;36(10):2887-94.

Pioglitazone Randomised Italian Study on Metabolic Syndrome (**PRISMA**): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D; PRISMA study group, Egan CG, China B, Bravi F, Di Pietro C. *J Endocrinol Invest*. 2013 Sep;36(8):606-16.

The METABOLIC Study: multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. Maggi S, Noale M, Pilotto A, Tiengo A, Cavallo Perin P, Crepaldi G; **Metabolic Working Group**. *Diabetes Metab*. 2013 May;39(3):236-43. doi: 10.1016/j.diabet.2013.02.003. Epub 2013 Mar 19.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA; **ALTITUDE Investigators**. *N Engl J Med*. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

Perinatal outcomes associated with the use of glargine during pregnancy. Di Cianni G, Torlone E, Lencioni C, Bonomo M, Di Benedetto A, Napoli A, Vitacolonna E, Mannino D, Lapolla A; **Italian Diabetes and Pregnancy Study Group; Italian Society of Diabetology**. *Diabet Med*. 2008 Aug;25(8):993-6.

Publications, fellowships, etc.:

More than 200 publications in International Journals of which 110 quoted in PUBMED as attached in the next section

October–December 1999 Italian CNR/Swedish MFR fellowship at the Rolf Luft Center for Diabetes Research, Karolinska Institutet, Sthocholm (SW) (Director Prof Holger Luthmann), project: "CANDIDATE GENES IN DIABETES AND HYPERTENSION"

October–December 1998 Italian CNR/Swedish MFR fellowship at the Rolf Luft Center for Diabetes Research, Karolinska Institutet, Sthocholm (SW) (Director Prof Holger Luthmann) project : "CANDIDATE GENES IN DIABETIC NEPHROPATHY"

Text Files - publication till 2020 as from PUBMED

Sex-Gender Differences in Diabetic Retinopathy

Sara Cherchi, Alfonso Gigante Maria Anna Spanu, Pierpaolo Contini, Gisella Meloni ,Maria Antonietta Fois, Danila Pistis , Rosangela M Pilosu, Alessio Lai , Salvatore Ruiu , Ilaria Campesi and Giancarlo Tonolo

International Journal of diabetology, April 2020/open access

Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.

Pasquini S, Da Prato G, **Tonolo G**, Bonora E, Trombetta M. Acta Diabetol. 2020 Jan;57(1):101-104. doi: 10.1007/s00592-019-01398-3. Epub 2019 Aug 9

Economic aspects in the management of diabetes in Italy.

Marcellusi A, Viti R, Sciattella P, Aimaretti G, De Cosmo S, Provenzano V, **Tonolo G**, Mennini FS. BMJ Open Diabetes Res Care. 2016 Oct 10;4(1):e000197. eCollection 2016.

The Effect of Sex and Gender on Diabetic Complications.

Seghieri G, Policardo L, Anichini R, Franconi F, Campesi I, Cherchi S, **Tonolo G**. Curr Diabetes Rev. 2017;13(2):148-160. doi: 10.2174/1573399812666160517115756. Review.

Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters.

Campesi I, Occhioni S, **Tonolo G**, Cherchi S, Basili S, Carru C, Zinellu A, Franconi F. Int J Med Sci. 2016 Feb 2;13(2):124-32. doi: 10.7150/ijms.14163. eCollection 2016.

Economic Aspects in the Management of Diabetes in Italy.

Marcellusi A, Viti R, Sciattella P, Aimaretti G, De Cosmo S, Provenzano V, **Tonolo G**, Mennini FS. BMJ open Diabetes research and care bmjdrc2016;4:e000197.doi:10.1136/bmjdr-2016-000197

Serum metabolomic profiles suggest influence of sex and oral contraceptive use.

Ruoppolo M, Campesi I, Scolamiero E, Pecce R, Caterino M, Cherchi S, Mercurio G, **Tonolo G**, Franconi F.

Am J Transl Res. 2014 Oct 11;6(5):614-24. eCollection 2014.

Tubulointerstitial disease in diabetic nephropathy.

Tonolo G, Cherchi S. Int J Nephrol Renovasc Dis. 2014 Mar 21;7:107-15. doi: 10.2147/IJNRD.S37883. eCollection 2014. Review.

Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans.

Campesi I, Carru C, Zinellu A, Occhioni S, Sanna M, Palermo M, **Tonolo G**, Mercurio G,

Franconi F. Am J Transl Res. 2013 Aug 15;5(5):497-509. eCollection 2013.

Oral contraceptives modify DNA methylation and monocyte-derived macrophage function.
Campesi I, Sanna M, Zinellu A, Carru C, Rubattu L, Bulzomi P, Seghieri G, **Tonolo G**, Palermo M, Rosano G, Marino M, Franconi F. Biol Sex Differ. 2012 Jan 27;3:4. doi: 10.1186/2042-6410-3-4.

Sex-gender differences in diabetes vascular complications and treatment.
Franconi F, Campesi I, Occhioni S, **Tonolo G**. Endocr Metab Immune Disord Drug Targets. 2012 Jun;12(2):179-96. Review.

6.

Mendelian breeding units versus standard sampling strategies: Mitochondrial DNA variation in southwest Sardinia.

Sanna D, Pala M, Cossu P, Dedola GL, Melis S, Fresu G, Morelli L, Obinu D, **Tonolo G**, Secchi G, Triunfo R, Lorenz JG, Scheinfeldt L, Torroni A, Robledo R, Francalacci P. Genet Mol Biol. 2011 Apr;34(2):187-94. Epub 2011 Apr 1.

7.

Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes.

Nosadini R, **Tonolo G**.

Nutr Metab Cardiovasc Dis. 2011 Feb;21(2):79-85. doi: 10.1016/j.numecd.2010.10.002. Epub 2010 Dec 24. Review.

8.

Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells.

Spinetti G, Fortunato O, Cordella D, Portararo P, Kränkel N, Katare R, Sala-Newby GB, Richer C, Vincent MP, Alhenc-Gelas F, **Tonolo G**, Cherchi S, Emanuelli C, Madeddu P. Circ Res. 2011 Feb 4;108(3):284-93. doi: 10.1161/CIRCRESAHA.110.236786. Epub 2010 Dec 16.

9.

Comparative sequence analysis of the non-protein-coding mitochondrial DNA of inbred rat strains.
Abhyankar A, Park HB, **Tonolo G**, Luthman H. PLoS One. 2009 Dec 7;4(12):e8148. doi: 10.1371/journal.pone.0008148.

Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control.

Thomaseth K, Pacini G, Morelli P, **Tonolo G**, Nosadini R. Nutr Metab Cardiovasc Dis. 2008 Nov;18(9):632-8. Epub 2007 Dec 3.

14.

Linkage Analysis: An Important Tool for Pre-Clinical Alport's Diagnosis.

Ciccarese M, **Tonolo G**, Faedda R, Cossu M, Spanu M, Luthman H, Satta A. Saudi J Kidney Dis Transpl. 2002 October-December;13(4):462-6.

15.

Clinical effects of mechanical periodontal therapy in type 2 diabetic patients.

Campus G, Salem A, Sacco G, Maida C, Cagetti MG, **Tonolo G**. Diabetes Res Clin Pract. 2007 Mar;75(3):368-9. Epub 2006 Aug 9. No abstract available.

16.

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R. Kidney Int. 2006 Jul;70(1):177-86. Epub 2006 May 17.

17.

A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients.

De Muro P, Fresu P, **Tonolo G**, Maioli M, Cherchi GB, Murgia A, Ibba C, Sanna GM, Cherchi GM. *Clin Chem Lab Med*. 2006;44(5):561-7.

18.

Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria.

Nosadini R, Velussi M, Brocco E, Abaterusso C, Carraro A, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, **Tonolo G**. *Diabetes*. 2006 Jan;55(1):234-9.

19.

Diabetes and periodontal disease: a case-control study.

Campus G, Salem A, Uzzau S, Baldoni E, **Tonolo G**. *J Periodontol*. 2005 Mar;76(3):418-25.

20.

Hyper-homocysteinemia is not a main feature of juvenile uncomplicated type 1 diabetes.

Meloni GF, **Tonolo GC**, Zuppi C, Zappacosta B, Musumeci S. *J Atheroscler Thromb*. 2005;12(1):14-9.

21.

Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms.

Nosadini R, Velussi M, Brocco E, Abaterusso C, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, **Tonolo G**. *Diabetes*. 2005 Jan;54(1):228-33.

22.

Duodenal switch without gastric resection: results and observations after 6 years.

Cossu ML, Noya G, **Tonolo GC**, Profili S, Meloni GB, Ruggiu M, Brizzi P, Cossu F, Pilo L, Tilocca PL.

Obes Surg. 2004 Nov-Dec;14(10):1354-9.

23.

Epitope-restricted 65-kilodalton glutamic acid decarboxylase autoantibodies among new-onset Sardinian type 2 diabetes patients define phenotypes of autoimmune diabetes.

Maioli M, Alejandro E, **Tonolo G**, Gilliam LK, Bekris L, Hampe CS, Obinu DA, Manconi A, Puddu L, Lynch K, Lernmark A; Study Group for the Genetics of Diabetes in Sardinia.

J Clin Endocrinol Metab. 2004 Nov;89(11):5675-82. 24.

The role of the renin angiotensin hormonal system in the metabolic syndrome and type 2 diabetes

.Nosadini R, **Tonolo G**. *Nutr Metab Cardiovasc Dis*. 2004 Apr;14(2):88-93. Review.

25.

Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status.

Brizzi P, **Tonolo G**, Bertrand G, Carusillo F, Severino C, Maioli M, Malaguarnera L, Musumeci S.

Clin Chem Lab Med. 2004 Feb;42(2):164-70.]

Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes. Nosadini R, Tonolo G.

J Nephrol. 2003 Nov-Dec;16 Suppl 7:S42-7. Review.

27.

Relationship between blood glucose control, pathogenesis and progression of diabetic nephropathy.

Nosadini R, Tonolo G.

J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S1-5. Review.

28.

Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer.

Brizzi P, Dessole S, Tonolo G, Capobianco G, Milia L, Puddu L, Nardo LG.

Reprod Biomed Online. 2003 Oct;7(3):309-12.

29.

About the pleiotropic effects of statins in human.

Tonolo G, Brizzi P, Melis MG, Secchi G, Maioli M.

Nephrol Dial Transplant. 2003 Jun;18(6):1234. No abstract available.

30.

Plasma lipids and lipoprotein changes after biliopancreatic diversion for morbid obesity.

Brizzi P, Angius MF, Carboni A, Cossu ML, Fais E, Noya G, Maioli M, Tonolo G.

Dig Surg. 2003;20(1):18-23.

31.

Plasma lipid composition and LDL oxidation.

Brizzi P, Tonolo G, Carusillo F, Malaguarnera M, Maioli M, Musumeci S.

Clin Chem Lab Med. 2003 Jan;41(1):56-60.

32.

Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.

Nosadini R, Tonolo G.

J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S216-23. Review.

33.

Insulin sensitivity correlates with glycogen synthesis rate, but not with von Willebrand factor in type 2 diabetes.

Sambataro M, Maioli M, Tonolo G, Stehouwer C, van Hinsbergh V, Piarulli F, Nosadini R, Pacini G.

Eur J Intern Med. 2002 Oct;13(7):439.

34.

The Trp64Arg beta3-adrenergic receptor amino acid variant confers increased sensitivity to the pressor effects of noradrenaline in Sardinian subjects.

Melis MG, Secchi G, Brizzi P, Severino C, Maioli M, Tonolo G.

Clin Sci (Lond). 2002 Oct;103(4):397-402.

35.

Urinary glycosaminoglycan and proteoglycan excretion in normoalbuminuric patients with type 1 diabetes mellitus.

De Muro P, Fresu P, Formato M, Tonolo G, Mamei M, Maioli M, Sanna GM, Cherchi GM.

J Nephrol. 2002 May-Jun;15(3):290-6.

36.

Low-dose dexamethasone in the rat: a model to study insulin resistance.

Severino C, Brizzi P, Solinas A, Secchi G, Maioli M, Tonolo G.

Am J Physiol Endocrinol Metab. 2002 Aug;283(2):E367-73.

37.

GAD65 and IA-2 autoantibodies are common in a subset of siblings of Sardinian Type 2 diabetes families.

Maioli M, Tonolo G, Bekris L, Cirillo R, Schranz D, Cossu E, Ciccarese M, Lernmark A; Study Group for the Genetics of Diabetes in Sardinia (SGGDS).

Diabetes Res Clin Pract. 2002 Apr;56(1):41-7.

38.

Identification of a new mutation in the alpha4(IV) collagen gene in a family with autosomal dominant Alport syndrome and hypercholesterolaemia.

Ciccarese M, Casu D, Ki Wong F, Faedda R, Arvidsson S, Tonolo G, Luthman H, Satta A. *Nephrol Dial Transplant*. 2001 Oct;16(10):2008-12.

39.

Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.

Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, Ciccarese M, Cherchi GM, Maioli M.

Eur J Clin Invest. 2000 Nov;30(11):980-7.

40.

A new locus for autosomal recessive hypercholesterolemia maps to human chromosome 15q25-q26.

Ciccarese M, Pacifico A, Tonolo G, Pintus P, Nikoshkov A, Zuliani G, Fellin R, Luthman H, Maioli M.

Am J Hum Genet. 2000 Feb;66(2):453-60.

41.

High plasma prorenin in non diabetic siblings of non insulin-dependent diabetes mellitus patients.

Glorioso N, Troffa C, Tonolo G, Filigheddu F, Dettori F, Ciccarese M, Saller A, Soro A, Brocco E, Pinna-Parpaglia P, Mantero F, Faronato PP, Nosadini R, Maioli M.

J Endocrinol Invest. 1999 Nov;22(10):760-5.

42.

Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate.

Solini A, Giacchetti G, Sfriso A, Fioretto P, Sardu C, Saller A, Tonolo G, Maioli M, Mantero F, Nosadini R.

Am J Kidney Dis. 1999 Dec;34(6):1002-9.

43.

Lipoprotein metabolism during normal pregnancy.

Brizzi P, Tonolo G, Esposito F, Puddu L, Dessole S, Maioli M, Milia S.

Am J Obstet Gynecol. 1999 Aug;181(2):430-4.

44.

Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population.

Tonolo G, Melis MG, Secchi G, Atzeni MM, Angius MF, Carboni A, Ciccarese M, Malavasi A, Maioli M.

J Hypertens. 1999 Jan;17(1):33-8.

45.

Serum apolipoprotein(a) concentrations and Apo(a) phenotypes in patients with liver cirrhosis.

Ciccarese M, Tonolo G, Brizzi P, Secchi G, Garrucciu G, Spanedda M, Salis S, Calvia P, Asara A, Wong FK, Maioli M, Realdi G.

Am J Gastroenterol. 1998 Sep;93(9):1505-9.

46.

Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT.

Pacini G, Tonolo G, Sambataro M, Maioli M, Ciccarese M, Brocco E, Avogaro A, Nosadini R.

Am J Physiol. 1998 Apr;274(4 Pt 1):E592-9.

47.

Biliopancreatic diversion preserving the stomach and pylorus in the treatment of hypercholesterolemia and diabetes type II: results in the first 10 cases.

Noya G, Cossu ML, Coppola M, Tonolo G, Angius MF, Fais E, Ruggiu M.

Obes Surg. 1998 Feb;8(1):67-72.

48.

Biliopancreatic diversion for treatment of morbid obesity: experience in 50 cases.

Noya G, Cossu ML, Coppola M, Tonolo G, Angius MF, Fais E, Ruggiu M.

Obes Surg. 1998 Feb;8(1):61-6.

49.

Lipoprotein(a): identification of subjects with a superbinding capacity for fibrinogen.

Scanu AM, Atzeni MM, Edelstein C, Tonolo G, Maioli M, Klezovitch O.

Clin Genet. 1997 Nov;52(5):367-70.

50.

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment.

Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M.

Diabetes Care. 1997 Dec;20(12):1891-5.

51.

Preliminary data on a genome search in NIDDM siblings: the NIDDM1 locus on chromosome 2 is not linked to NIDDM in the Sardinian population. Study Group for the Genetics of Diabetes in Sardinia.

Ciccarese M, Tonolo G, Delin I, Wong FK, Holm P, Atzeni MM, Lichtenstein P, Kockum I, Maioli M, Luthman H.

Diabetologia. 1997 Nov;40(11):1366-7. No abstract available.

52.

Glucagon receptor Gly40Ser amino acid variant in Sardinian hypertensive non-insulin-dependent diabetic patients. Sardinian Diabetic Genetic Study Group (SDGSG).

Tonolo G, Melis MG, Ciccarese M, Secchi G, Atzeni MM, Li LS, Luthman H, Maioli M.

Acta Diabetol. 1997 Aug;34(2):75-6.

53.

Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group.

Faronato PP, Maioli M, Tonolo G, Brocco E, Noventa F, Piarulli F, Abaterusso C, Modena F, de Bigontina G, Velussi M, Inchiostro S, Santeusano F, Buetti A, Nosadini R.

Diabetologia. 1997 Jul;40(7):816-23.

54.

Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta-thalassemia.

Maioli M, Vigna GB, Tonolo G, Brizzi P, Ciccarese M, Donegà P, Maioli M, Fellin R.

Atherosclerosis. 1997 May;131(1):127-33.

55.

Physiological and genetic characterization of the Gly40Ser mutation in the glucagon receptor gene in the Sardinian population. The Sardinian Diabetes Genetic Study Group.

Tonolo G, Melis MG, Ciccarese M, Secchi G, Atzeni MM, Maioli M, Pala G, Massidda A, Manai M, Pilosu RM, Li LS, Luthman H, Maioli M.

Diabetologia. 1997 Jan;40(1):89-94.

56.

A new missense mutation in the glucokinase gene in an Italian Mody family.

Bertini C, Maioli M, Fresu P, Tonolo G, Pirastu M, Maioli M.

Diabetologia. 1996 Nov;39(11):1413-4. No abstract available.

57.

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.

Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R.

Diabetes. 1996 Feb;45(2):216-22.

58.

Plasma clearance rate of ⁵¹Cr-EDTA provides a precise and convenient technique for

measurement of glomerular filtration rate in diabetic humans.

Sambataro M, Thomasset K, Pacini G, Robaudo C, Carraro A, Bruseghin M, Brocco E, Abaterusso C, DeFerrari G, Fioretto P, Maioli M, Tonolo GC, Crepaldi G, Nosadini R. *J Am Soc Nephrol.* 1996 Jan;7(1):118-27.

59.

Cyclical variation of plasma lipids, apolipoproteins, and lipoprotein(a) during menstrual cycle of normal women.

Tonolo G, Ciccarese M, Brizzi P, Milia S, Dessole S, Puddu L, Secchi G, Maioli M. *Am J Physiol.* 1995 Dec;269(6 Pt 1):E1101-5.

60.

Mildly raised corticosterone excretion rates in patients with essential hypertension.

Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R.

J Hum Hypertens. 1995 Jun;9(6):391-3.

61.

Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.

Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R.

Hypertension. 1995 Jan;25(1):67-70.

62.

Recognition of markers of response to potassium-canrenoate in essential hypertension.

Glorioso N, Tonolo G, Troffa C, Soro A, Manunta P, Madeddu P, Sabino G, Pinna-Parpaglia P, Realdi G.

Steroids. 1995 Jan;60(1):105-9.

63.

Bradykinin B2-receptor blockade facilitates deoxycorticosterone-salt hypertension.

Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Tonolo G, Troffa C, Glorioso N.

Hypertension. 1993 Jun;21(6 Pt 2):980-4.

64.

Effect of chronic intracerebroventricular dexamethasone on blood pressure in normotensive rats.

Tonolo G, Soro A, Madeddu P, Troffa C, Melis MG, Patteri G, Parpaglia PP, Sabino G, Maioli M, Glorioso N.

Am J Physiol. 1993 Jun;264(6 Pt 1):E843-7.

65.

Atrial natriuretic factor and changes in the aldosterone response to angiotensin II in sodium depleted dogs.

Richards AM, Tree M, Tonolo G, Montorsi P, Polonia J, Morton JJ, Fraser R, Frampton C.

Clin Exp Hypertens. 1993 Mar;15(2):379-94.

66.

Different sensitivity to hydrochlorothiazide and to potassium-canrenoate among essential hypertensive patients.

Glorioso N, Melis MG, Manunta P, Troffa C, Tonolo G, Soro A, Madeddu P, Pazzola A, Pala F, Cusi D, et al.

Clin Exp Hypertens. 1993;15 Suppl 1:187-96.

67.

Raised serum apolipoprotein (a) in active diabetic retinopathy.

Maioli M, Tonolo G, Pacifico A, Ciccarese M, Brizzi P, Kohner EM, Porta M.

Diabetologia. 1993 Jan;36(1):88-90.

68.

Effects of Hoe 140, a bradykinin B2-receptor antagonist, on renal function in conscious normotensive rats.

Madeddu P, Anania V, Parpaglia PP, Demontis MP, Varoni MV, Pisanu G, Troffa C, Tonolo G, Glorioso N.

Br J Pharmacol. 1992 Jun;106(2):380-6.

69.

Role of brain kallikrein-kinin system in regulation of adrenocorticotropin release.

Madeddu P, Anania V, Alagna S, Troffa C, Parpaglia PP, Tonolo G, Demontis MP, Varoni MV, Fattaccio C, Glorioso N.

Am J Physiol. 1992 Mar;262(3 Pt 1):E312-8.

70.

Familial insulinoma: description of two cases.

Maioli M, Ciccarese M, Pacifico A, Tonolo G, Ganau A, Cossu S, Tanda F, Realdi G.

Acta Diabetol. 1992;29(1):38-40.

71.

Stroke volume and left heart anatomy in relation to plasma volume in essential hypertension.

Ganau A, Arru A, Saba PS, Piga G, Glorioso N, Tonolo G, Madeddu G, Bianchi G.

J Hypertens Suppl. 1991 Dec;9(6):S150-1. No abstract available.

72.

Endothelin-1-induced renal vasoconstriction is blunted by enalaprilat and enhanced by EDRF antagonist in awake normotensive rats.

Madeddu P, Anania V, Parpaglia PP, Troffa C, Pazzola A, Soro A, Manunta P, Tonolo G, Demontis MP, Varoni MV, et al.

Clin Invest Med. 1991 Dec;14(6):600-6.

73.

Prorenin is present in human red blood cells.

Troffa C, Tonolo G, Manunta P, Pazzola A, Soro A, Madeddu P, Pala F, Melis MG, PinnaParpaglia P, Patteri G, et al.

Can J Physiol Pharmacol. 1991 Sep;69(9):1394-7.

74.

Effect of angiotensin converting enzyme inhibition on the menstrual cycle of hypertensive women.

Troffa C, Tonolo G, Melis MG, Manunta P, Soro A, Pala F, Pazzola A, Sabino G, Masala A, Maioli M, et al.

J Cardiovasc Pharmacol. 1991 Sep;18(3):462-7.

75.

A case of hyperglycemic hyperosmolar non-ketotic coma during anesthesia: a possible cause of failed re-awakening.

Maioli M, Arca GM, Ganau A, Mastroni P, Pacifico A, Padua G, Piredda G, Solinas G, Tonolo G, Ruiu P.

Diabetes Res. 1991 Sep;18(1):45-8.

76.

Efficacy of nifedipine to prevent systemic and renal vasoconstrictor effects of endothelin.

Madeddu P, Yang XP, Anania V, Troffa C, Pazzola A, Soro A, Manunta P, Tonolo G, Demontis MP, Varoni MV, et al.

Am J Physiol. 1990 Aug;259(2 Pt 2):F304-11.

77.

[Protective effect of a calcium antagonist against renal vasoconstriction induced by endothelin in the normotensive rat].

Madeddu P, Pala F, Troffa C, Pinna Parpaglia P, Pazzola A, Soro A, Manunta P, Tonolo G, Melis MG, Demontis MP, et al.

Boll Soc Ital Biol Sper. 1990 Jul;66(7):671-8. Italian.

78.

[Effect of chronic enalapril treatment on prorenin, renin and sex hormones during the menstrual

cycle in patients with essential hypertension].

Troffa C, Tonolo G, Manunta P, Pinna Parpaglia P, Madeddu P, Melis MG, Soro A, Pala F, Pazzola A, Patteri G, et al.

Boll Soc Ital Biol Sper. 1990 Jul;66(7):663-70. Italian.

79.

[Effect of menstrual cycle hormones on cation transport in the red-cell membrane].

Melis MG, Troffa C, Manunta P, Pinna Parpaglia P, Soro A, Pala F, Madeddu P, Pazzola A, Tonolo G, Patteri G, et al.

Boll Soc Ital Biol Sper. 1990 Jul;66(7):679-84. Italian.

80.

Effects of dexamethasone on body fluid and electrolyte composition of rats.

Kenyon CJ, Brown WB, Fraser R, Tonolo G, McPherson F, Davies DL.

Acta Endocrinol (Copenh). 1990 May;122(5):599-604.

81.

Brain kinins are responsible for the pressor effect of intracerebroventricular captopril in spontaneously hypertensive rats.

Madeddu P, Glorioso N, Soro A, Tonolo G, Manunta P, Troffa C, Demontis MP, Varoni MV, Anania V.

Hypertension. 1990 Apr;15(4):407-12.

82.

Effect of a kinin antagonist on renal function and haemodynamics during alterations in sodium balance in conscious normotensive rats.

Madeddu P, Glorioso N, Soro A, Manunta P, Troffa C, Tonolo G, Grazia Melis M, Pazzola A.

Clin Sci (Lond). 1990 Feb;78(2):165-8.

83.

Changes in plasma atrial natriuretic factor during sequential fluid removal and biochemical correction in end-stage chronic renal failure patients.

Tonolo G, McMillan M, Richards AM, Montorsi P, Polonia J, Soro A, Troffa C, Glorioso N.

Nephron. 1990;55(1):58-62.

84.

Activation of human prorenin by lipidic constituents of the cell membrane.

Glorioso N, Troffa C, Tonolo G, Manunta P, Madeddu P, Melis MG, Pazzola A, Pala F, Maioli M, Mameli P, et al.

Am J Hypertens. 1989 Dec;2(12 Pt 1):920-3.

85.

Stimulation of plasma inactive renin by dexamethasone in the cat.

Glorioso N, Troffa C, Tonolo G, Melis MG, Manunta P, Soro A, Madeddu P, Pazzola A, Pala F.

Am J Physiol. 1989 Dec;257(6 Pt 1):E879-84.

86.

Circulating prorenin and renin in response to intravenous adrenocorticotrophic hormone in essential hypertension.

Troffa C, Tonolo G, Soro A, Manunta P, Melis MG, Pazzola A, Pala F, Madeddu P, Alagna S, Masala A, et al.

J Hypertens Suppl. 1989 Dec;7(6):S226-7.

87.

Correlates of atrial natriuretic factor in chronic renal failure.

Tonolo G, Soro A, Scardaccio V, Troffa C, Pazzola A, Manunta P, Melis MG, Pala F, Madeddu P, Rovasio PP, et al.

J Hypertens Suppl. 1989 Dec;7(6):S238-9.

88.

Effect of endothelin on regional hemodynamics and renal function in awake normotensive rats.

- Madeddu P, Troffa C, Glorioso N, Pazzola A, Soro A, Manunta P, Tonolo G, Demontis MP, Varoni MV, Anania V.
J Cardiovasc Pharmacol. 1989 Dec;14(6):818-25.
89.
[Possible activation of human prorenin by contact with the cell membrane].
Troffa C, Tonolo G, Manunta P, Pazzola A, Melis MG, Pala F, Soro A, Madeddu P, Glorioso N.
Boll Soc Ital Biol Sper. 1989 Nov;65(11):1017-23. Italian.
90.
[Erythrocyte cation transport in arterial hypertension: interrelation with the renin-angiotensin-aldosterone system and the atrial natriuretic factor].
Manunta P, Melis MG, Soro A, Pazzola A, Troffa C, Motzo S, Pala F, Madeddu P, Tonolo G, Glorioso N.
Boll Soc Ital Biol Sper. 1989 Nov;65(11):1009-16. Italian.
91.
Low-dose infusion of atrial natriuretic factor in mild essential hypertension.
Tonolo G, Richards AM, Manunta P, Troffa C, Pazzola A, Madeddu P, Towrie A, Fraser R, Glorioso N.
Circulation. 1989 Oct;80(4):893-902.
92.
Similarity between active and trypsin-activated inactive renin in dog plasma by means of renin inhibition: the dog as an animal model for studies of inactive renin.
Tonolo G, Tree M, Pazzola A, Leckie BJ.
J Hypertens. 1988 Dec;6(12):975-80.
93.
Contrasting plasma atrial natriuretic factor concentrations during comparable natriuresis with infusions of atrial natriuretic factor and saline in normal man.
Richards AM, Tonolo G, Polonia J, Montorsi P.
Clin Sci (Lond). 1988 Nov;75(5):455-62.
94.
Plasma clearance and effects of alpha-hANP infused in patients with end-stage renal failure.
Tonolo G, McMillan M, Polonia J, Pazzola A, Montorsi P, Soro A, Glorioso N, Richards MA.
Am J Physiol. 1988 Jun;254(6 Pt 2):F895-9.
95.
Atrial natriuretic peptides and renin release.
Richards AM, Tonolo G, Tree M, Robertson JI, Montorsi P, Leckie BJ, Polonia J.
Am J Med. 1988 Mar 11;84(3A):112-8.
96.
Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man.
Richards AM, Tonolo G, Montorsi P, Finlayson J, Fraser R, Inglis G, Towrie A, Morton JJ.
J Clin Endocrinol Metab. 1988 Mar;66(3):465-72.
97.
Prorenin in the cells of the mature human ovarian follicle.
Glorioso N, Troffa C, Tonolo G.
Clin Exp Hypertens A. 1988;10(6):1325-7.
98.
Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atrial natriuretic peptide.
Tonolo G, Fraser R, Connell JM, Kenyon CJ.
J Hypertens. 1988 Jan;6(1):25-31.
99.
Effects of nitrendipine on blood pressure, renin-angiotensin system, and kidney function in

essential hypertension.

Glorioso N, Manunta P, Troffa C, Pazzola A, Soro A, Pala F, Melis MG, Madeddu P, Tonolo G.
J Cardiovasc Pharmacol. 1988;12 Suppl 4:S142-5.
100.

Correlates of plasma atrial natriuretic factor in health and hypertension.

Montorsi P, Tonolo G, Polonia J, Hepburn D, Richards AM.
Hypertension. 1987 Dec;10(6):570-6.
101.

Diurnal change in plasma atrial natriuretic peptide concentrations.

Richards AM, Tonolo G, Fraser R, Morton JJ, Leckie BJ, Ball SG, Robertson JI.
Clin Sci (Lond). 1987 Nov;73(5):489-95.
102.

Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system.

Madeddu P, Oppes M, Soro A, Dessì-Fulgheri P, Glorioso N, Bandiera F, Manunta P, Rubattu S, Troffa C, Tonolo GC, et al.
J Cardiovasc Pharmacol. 1987 May;9(5):536-40.
103.

Dopamine affects angiotensin II-induced steroidogenesis by altering clearance of the peptide in man.

Connell JM, Tonolo G, Davies DL, Finlayson J, Ball SG, Inglis G, Fraser R.
J Endocrinol. 1987 Apr;113(1):139-46.

104.

Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods.

Richards AM, Tonolo G, McIntyre GD, Leckie BJ, Robertson JI.
J Hypertens. 1987 Apr;5(2):227-36.
105.

Plasma atrial natriuretic peptide concentrations during exercise in sodium replete and deplete normal man.

Richards AM, Tonolo G, Cleland JG, McIntyre GD, Leckie BJ, Dargie HJ, Ball SG, Robertson JI.
Clin Sci (Lond). 1987 Feb;72(2):159-64.
106.

Comparison of sublingual and oral captopril in hypertension.

Dessì-Fulgheri P, Bandiera F, Rubattu S, Cocco F, Madeddu P, Oppes M, Tonolo GC, Glorioso N, Rappelli A.
Clin Exp Hypertens A. 1987;9(2-3):593-7.
107.

Effect of nitrendipine on blood pressure, plasma renin, and exchangeable sodium in DOC-salt hypertension in the rat.

Otipka NA, Tonolo G, Brown WB, Robertson JI.
J Cardiovasc Pharmacol. 1987;10 Suppl 10:S140-2.
108.

Plasma atrial natriuretic peptide: responses to modest and severe sodium restriction.

Richards AM, Tonolo G, Cleland JG, Leckie BJ, McIntyre GD, Ingram M, Dargie HJ, Ball SG, Robertson JI.
J Hypertens Suppl. 1986 Dec;4(6):S559-63.
109.

Plasma alpha natriuretic peptide in cardiac impairment.

Richards AM, Cleland JG, Tonolo G, McIntyre GD, Leckie BJ, Dargie HJ, Ball SG, Robertson JI.

Br Med J (Clin Res Ed). 1986 Aug 16;293(6544):409-12.

110.

Prokallikrein and kallikrein inhibitors in human urine.

Madeddu P, Oppes M, Rubattu S, Tonolo GC, Dessì-Fulgheri P, Glorioso N, Rappelli A.

J Hypertens Suppl. 1985 Dec;3(3):S283-6.

111.

[Long-term therapeutic efficacy of captopril in the treatment of essential and secondary hypertension].

Glorioso N, Madeddu P, Dessì Fulgheri P, Oppes M, Tonolo GC, Bandiera F, Manca G, Rappelli A.

Minerva Cardioangiol. 1984 Jul-Aug;32(7-8):467-71. Italian. No abstract available.

112.

Trypsin-activatable inactive renin in rat plasma.

Glorioso N, Madeddu P, Dessì-Fulgheri P, Fois G, Meloni F, Bandiera F, Tonolo G, Rappelli A.

Clin Sci (Lond). 1983 Feb;64(2):137-40.

113.

Active and inactive renin during acute reduction of renal perfusion pressure in essential hypertensives.

Glorioso N, Dessì-Fulgheri P, Madeddu P, Urigo F, Tonolo GC, Oppes M, Palermo M, Rappelli A.

Clin Exp Hypertens A. 1982;4(11-12):2293-302.